Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000071.xml
Download PDF
Semin Neurol 2007; 27(2): 159-169
DOI: 10.1055/s-2007-971169
DOI: 10.1055/s-2007-971169
Tardive Dyskinesia
Further Information
Publication History
Publication Date:
27 March 2007 (online)
ABSTRACT
This article provides up-to-date information regarding clinical manifestations, pathophysiology, and evidence-based treatment for tardive dyskinesia (TD). We conducted a comprehensive literature search, including sources such as the Cochrane Library, EMBASE, and Medline; and we manually searched bibliographic references. We also contacted the authors of each included trial. All randomized clinical trials that compared different types of active interventions with placebo or no intervention in patients with neuroleptic-induced TD were included in our data. Two reviewers independently applied the selection criteria to all identified references, appraised the methodological quality of each trial, and extracted the relevant data. Relative risks and 95% confidence intervals were estimated using the fixed effect model. More than 500 randomized trials evaluating over 90 different interventions to treat TD were identified. From those, 45 trials were included in the current reviews. None of the trials pooled on these reviews found a definitive therapy for TD. Clinicians faced with conditions such as TD should carefully weigh the risks and benefits involved with any given intervention.
KEYWORDS
Tardive dyskinesia - antipsychotics - neuroleptic-induced movement disorders
REFERENCES
- 1 Schonecker M. Ein eigentumliches Syndrom im oralem Bereich bei Megaphenapplikation. Nervenarzt. 1957; 28 550-553
- 2 Sigwald J, Bouttier D, Raymondeaud C, Piot C. Quatre cas de dyskinesie facio-bucco-linguo-masticatrice a l'evolution prolongee secondaire a un traitement par less neuroleptiques. Rev Neurol (Paris). 1959; 100 751-755
- 3 Faurbye A, Rasch P, Peterson P, Brandborg G, Pakkenberg H. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand. 1964; 40 10-27
- 4 Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol. 1995; 18 197-214
- 5 Yassa R, Lai S. Respiratory irregularity and tardive dyskinesia. Acta Psychiatr Scand. 1986; 73 506-510
- 6 Fenn D S, Moussaoui D, Hoffman W F et al.. Movements in never-medicated schizophrenics: a preliminary study. Psychopharmacology (Berl). 1996; 123 206-210
- 7 Fenton W S, Blyler C R, Wyatt R J, McGlashan T H. Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br J Psychiatry. 1997; 171 265-268
- 8 Kane J M, Woerner M, Borenstein M et al.. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull. 1986; 22 254-258
- 9 Barnes T R, Kidger T, Gore S M. Tardive dyskinesia: a 3-year follow-up study. Psychol Med. 1983; 13 71-81
- 10 Kane J M, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol. 1988; 8(suppl) 52S-56S
- 11 Gardos G, Casey D, Cole J et al.. Ten-year outcome of tardive dyskinesia. Am J Psychiatry. 1994; 151 836-841
- 12 Halliday J, Farrington S, MacDonald S, MacEwan T, Sharley V, McCreadie R. Nithsdale Schizophrenia Survey 23: movement disorders-20 year review. Br J Psychiatry. 2002; 181 422-427
- 13 Kane J M, Smith J M. Tardive dyskinesia: prevalence and risk factors. Arch Gen Psychiatry. 1982; 39 473-481
- 14 Muscettola G, Pampallona S, Barbato G, Casiello M, Bolini P. Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiatr Scand. 1993; 87 29-36
- 15 Jeste D V, Caliguiri M P. Tardive dyskinesia (review). Schizophr Bull. 1993; 19 303-315
- 16
Jeste D V.
Tardive dyskinesia in older patients.
J Clin Psychiatry.
2000;
61(suppl 4)
27-32
MissingFormLabel
- 17 Wegner J T, Kane J M. Follow-up study on the reversibility of tardive dyskinesia. Am J Psychiatry. 1982; 139 368-369
- 18 Klawans H L, Tanner C M, Barr A. The reversibility of “permanent” tardive dyskinesia. Clin Neuropharmacol. 1984; 7 153-159
- 19 Casey D E, Povlsen U J, Meidahl B et al.. Neuroleptic-induced tardive dyskinesia and parkinsonism: change during several years of continuing treatment. Psychopharmacol Bull. 1986; 22 250-253
- 20 Yagi G, Itoh H. A 10-year follow-up study of tardive dyskinesia with special reference to the influence of neuroleptic administration on the long-term prognosis. Keio J Med. 1985; 34 211-219
- 21 Gardos G, Cole J O, Haskell D et al.. The natural history of tardive dyskinesia. J Clin Psychopharmacol. 1988; 8(suppl) 31S-37S
- 22 Fernandez H H, Krupp B, Friedman J H. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology. 2001; 56 805-807
- 23 Hitri A, Weiner W, Borison R et al.. Dopamine binding following prolonged haloperidol pretreatment. Ann Neurol. 1978; 3 134-140
- 24 Klawans H L, Tanner C M, Goetz C G. Epidemiology and pathophysiology of tardive dyskinesia. Adv Neurol. 1988; 49 185-197
- 25 Steen V M, Lovlie R, MacEwan T, McCreadie R G. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry. 1997; 2 139-145
- 26 Tsai G, Goff D, Chang R, Flood J, Baer L, Coyle J. Markers of glutamitergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry. 1998; 155 1207-1213
- 27 Lohr J B. Oxygen radicals and neuropsychiatric illness: some speculations. Arch Gen Psychiatry. 1991; 48 1097-1106
- 28 Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev. 2006; (3) CD000459
- 29 El-Sayeh H G, Lyra da Silva J P, Rathbone J, Soares-Weiser K. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2006; (1) CD000458
- 30 Soares K, Rathbone J, Deeks J. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2004; (4) CD000203
- 31 Soares K V, McGrath J J. Anticholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2000; (2) CD000204
- 32 Soares K V, McGrath J J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2001; (4) CD000209
- 33 Soares-Weiser K, Rathbone J. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2004; (1) CD000206
- 34 Soares-Weiser K, Rathbone J. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2000; (2) CD000204
- 35 Soares-Weiser K V, Joy C. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2003; (2) CD000208
- 36 Tammenmaa I A, McGrath J J, Sailas E, Soares-Weiser K. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2002; (3) CD000207
- 37 Tammenmaa I A, Sailas E, McGrath J J, Soares-Weiser K, Wahlbeck K. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28 1099-1107
- 38
Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] . Higgins JPT, Green S In: The Cochrane Library. Chichester, UK; John Wiley & Sons, LtdMissingFormLabel - 39 Higgins J P, Thompson S G. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21 1539-1558
- 40 Egger M, Davey-Smith G, Altman D G. Systematic reviews in health care: meta-analysis in context. London; BMJ Publishing Group 2001: 487
MissingFormLabel
- 41 Nordic Dyskinesia Study Group . Effect of different neuroleptics in tardive dyskinesia and parkinsonism: a video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology (Berl). 1986; 90 423-429
- 42 Double D B, Warren G C, Evans M, Rowlands R P. Efficacy of maintenance use of anticholinergic agents. Acta Psychiatr Scand. 1993; 88 381-384
- 43 Elie R, Morin L, Tetreault L. Effets de l'ethopropazine et du trihexyphenidyle sur quelques parametres du syndrome neuroleptique. Encephale. 1972; 61 32-52
- 44 Friis T, Christensen T R, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia: a double-blind cross-over study with placebo. Acta Psychiatr Scand. 1983; 67 178-187
- 45 Gardos G, Cole J O, Rapkin R M et al.. Anticholinergic challenge and neuroleptic withdrawal: changes in dyskinesia and symptom measures. Arch Gen Psychiatry. 1984; 41 1030-1035
- 46 Gerlach J, Simmelsgaard H. Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine. Psychopharmacology (Berl). 1978; 59 105-112
- 47 Greil W, Haag H, Rossnagl G, Ruther E. Effect of anticholinergics on tardive dyskinesia: a controlled discontinuation study. Br J Psychiatry. 1984; 145 304-310
- 48 Klett C J, Caffey Jr E J. Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics. Arch Gen Psychiatry. 1972; 26 374-379
- 49 Csernansky J G, Tacke U, Rusen D, Hollister L E. The effect of benzodiazepines on tardive dyskinesia symptoms. J Clin Psychopharmacol. 1988; 8 154-155
- 50 Weber S S, Dufresne R L, Becker R E, Mastrati P. Diazepam in tardive dyskinesia. Drug Intell Clin Pharm. 1983; 17 523-527
- 51 Kojima T, Yamauchi T, Miyasaka M et al.. Treatment of tardive dyskinesia with ceruletide: a double-blind, placebo-controlled study. Psychiatry Res. 1992; 43 129-136
- 52 Matsunaga T, Ohyama S, Takehara S et al.. The effect of ceruletide on tardive dyskinesia: a double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 1988; 12 533-539
- 53 Buruma O J, Roos R A, Bruyn G W, Kemp B, van-der-Velde E. Tiapride in the treatment of tardive dyskinesia. Acta Neurol Scand. 1982; 65 38-44
- 54 Hebenstreit G F, Hoffmann H, Hoffmann W, Pittner H. [beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics]. Wien Klin Wochenschr. 1986; 98 388-392
- 55 Beckham B. Lecithin Therapy for Tardive Dyskinesia [dissertation]. Denton; North Texas State University 1981
MissingFormLabel
- 56 Bockenheimer S, Lucius G. [Deanol in tardive dyskinesia: a double-blind study (author's transl)]. Arch Psychiatr Nervenkr. 1976; 222 69-75
- 57 de Montigny C, Annable L. Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study. Psychopharmacology (Berl). 1979; 65 219-223
- 58 Gelenberg A J, Dorer D J, Wojcik J D, Falk W E, Brotman A W, Leahy L. A crossover study of lecithin treatment of tardive dyskinesia. J Clin Psychiatry. 1990; 51 149-153
- 59 George J, Pridmore S, Aldous D. Double blind controlled trial of deanol in tardive dyskinesia. Aust N Z J Psychiatry. 1981; 15 68-71
- 60 Jackson I. Cholinergic enhancement in tardive dyskinesia. Current Therapeutic Research. 1978; 24 725-733
- 61 Jackson I V, Nuttall E A, Ibe I O, Perez-Cruet J. Treatment of tardive dyskinesia with lecithin. Am J Psychiatry. 1979; 136 1458-1460
- 62 Kocher R, Hobi V, Linder M, Studer K. [Treatment with dimethylaminoathanol (deanol) in neuroleptic induced tardive dyskinesia]. Schweiz Arch Neurol Neurochir Psychiatr. 1980; 126 103-109
- 63 Price L. Lecithin Treatment for Tardive Dyskinesia: A Clinical Evaluation [Ph.D. dissertation]. Denton; North Texas State University 1982: 147
MissingFormLabel
- 64 Tarsy D, Bralower M. Deanol acetamidobenzoate treatment in choreiform movement disorders. Arch Neurol. 1977; 34 756-758
- 65 Yagi G, Kamijima K, Miura S. Meclofenoxate hydrochloride (Lucidril) in tardive dyskinesia: a double-blind placebo-controlled study. Rinsho Hyoka. 1990; 18 455-479
- 66 Ananth J, Djenderedjian A, Beshay M, Kamal M, Kodjian A, Barriga C. Baclofen in the treatment of tardive dyskinesia. Curr Ther Res Clin Exp. 1987; 42 111-114
- 67 Burner M, Giroux C, Lheritier C, Garreau M, Morselli P. Preliminary observations on the therapeutic action of progabide in tardive dyskinesia. Brain Dysfunction. 1989; 2 289-296
- 68 Fisk G G, York S M. The effect of sodium valproate on tardive dyskinesia-revisited. Br J Psychiatry. 1987; 150 542-546
- 69 Gerlach J, Rye T, Kristjansen P. Effect of baclofen on tardive dyskinesia. Psychopharmacology (Berl). 1978; 56 145-151
- 70 Linnoila M, Viukari M, Kietala O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry. 1976; 129 114-119
- 71 Nair N P, Yassa R, Ruiz-Navarro J, Schwartz G. Baclofen in the treatment of tardive dyskinesia. Am J Psychiatry. 1978; 135 1562-1563
- 72 Stewart R M, Rollins J, Beckam B. Baclofen in tardive dyskinesia patients maintained on neuroleptics. Clin Neuropharmacol. 1982; 5 365-373
- 73 Thaker G K, Tamminga C A, Alphs L D, Lafferman J, Ferraro T N, Hare T A. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia: reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment. Arch Gen Psychiatry. 1987; 44 522-529
- 74 Wolkin A, Jordan B, Peselow E, Rubinstein M, Rotrosen J. Essential fatty acid supplementation in tardive dyskinesia. Am J Psychiatry. 1986; 143 912-914
- 75 Mouret J, Khomais M, Lemoine P, Sebert P. Low doses of insulin as a treatment of tardive dyskinesia: conjuncture or conjecture?. Eur Neurol. 1991; 31 199-203
- 76 Mackay A V, Sheppard G P, Saha B K, Motley B, Johnson A L, Marsden C D. Failure of lithium treatment in established tardive dyskinesia. Psychol Med. 1980; 10 583-587
- 77 Cookson I B. The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. Int Clin Psychopharmacol. 1987; 2 141-149
- 78 Kane J M, Rifkin A, Woerner M et al.. Low-dose neuroleptic treatment of outpatient schizophrenics. I: preliminary results for relapse rates. Arch Gen Psychiatry. 1983; 40 893-896
- 79 Emsley R, Turner H J, Schronen J, Botha K, Smit R, Oosthuizen P P. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004; 65 696-701
- 80 Glazer W M, Hafez H. A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophr Res. 1990; 3 315-320
- 81 Kazamatsuri H, Chien C, Cole J. Treatment of tardive dyskinesia. II: short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Arch Gen Psychiatry. 1972; 27 100-103
- 82 Glazer W M, Naftolin F, Morgenstern H, Barnea E R, MacLusky N J, Brenner L M. Estrogen replacement and tardive dyskinesia. Psychoneuroendocrinology. 1985; 10 345-350
- 83 Mosnik D M, Spring B, Rogers K, Baruah S. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients. Neuropsychopharmacology. 1997; 16 136-146
- 84 Adler L A, Peselow E, Rotrosen J et al.. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry. 1993; 150 1405-1407
- 85 Adler L A, Rotrosen J, Edson R et al.. Vitamin E in the treatment of tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry. 1999; 56 836-841
- 86 Akhtar S, Jajor T, Kumar S. Vitamin E in the treatment of tardive dyskinesia. J Postgrad Med. 1993; 39 124-126
- 87 Dabiri L M, Pasta D, Darby J K, Mosbacher D. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am J Psychiatry. 1994; 151 925-926
- 88 Egan M F, Hyde T M, Albers G W et al.. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry. 1992; 149 773-777
- 89 Elkashef A M, Ruskin P E, Bacher N, Barrett D. Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatry. 1990; 147 505-506
- 90 Lam L C, Chiu H F, Hung S F. Vitamin E in the treatment of tardive dyskinesia: a replication study. J Nerv Ment Dis. 1994; 182 113-114
- 91 Lohr J B, Caligiuri M P. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry. 1996; 57 167-173
- 92 Sajjad S H. Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at different doses. Int Clin Psychopharmacol. 1998; 13 147-155
- 93 Schmidt M, Meister P, Baumann P. Treatment of tardive dyskinesias with vitamin E. Eur Psychiatry. 1991; 6 201-207
- 94 Soares K V, McGrath J J. The treatment of tardive dyskinesia: a systematic review and meta-analysis. Schizophr Res. 1999; 39 1-16 discussion 17-18
- 95 Weber S S, Dufresne R L, Becker R E, Mastrati P. Diazepam in tardive dyskinesia. Drug Intell Clin Pharm. 1983; 17 523-527
Hubert H FernandezM.D.
Program Director, Neurology Residency Training Program, University of Florida/McKnight
Brain Institute
PO Box 100236, Gainesville, FL 32610